Journal of South Asian Federation of Obstetrics and Gynaecology

Register      Login

VOLUME 12 , ISSUE 6 ( November-December, 2020 ) > List of Articles

CASE REPORT

Story of Management of a Challenging Case of a Fibrotic Uterine Cavity

Nidhi Jain, Hena Kausar, Rahul Manchanda, Sravani Chithra, Anshika Lekhi

Keywords : Asherman\'s syndrome, Hysteroscopy, Intrauterine adhesions, Metroplasty

Citation Information : Jain N, Kausar H, Manchanda R, Chithra S, Lekhi A. Story of Management of a Challenging Case of a Fibrotic Uterine Cavity. J South Asian Feder Obs Gynae 2020; 12 (6):432-435.

DOI: 10.5005/jp-journals-10006-1829

License: CC BY-NC 4.0

Published Online: 12-04-2021

Copyright Statement:  Copyright © 2020; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Aim: Our aim is to highlight the emerging trends of management of a moderate-to-severe degree of Asherman\'s syndrome/fibrotic uterine cavity in the form of either relook hysteroscopic surgery or postoperative hormonal therapy. Background: Asherman\'s syndrome also known as Fritsch syndrome or Fritsch–Asherman syndrome is a condition where iatrogenic intrauterine adhesions (IUA) develop and it occurs most commonly following dilatation and curettage or pelvic infections, e.g., endometrial tuberculosis. Diagnosis is based on the history and a high index of suspicion followed by confirmation by saline infusion sonography (SIS) or hysterosalpingography (HSG). Hysteroscopy is the gold standard for both diagnosis and treatment of Asherman\'s syndrome. This case highlights the importance of hysteroscopic management of a known case of Asherman\'s syndrome/IUA and also highlights how important are relook hysteroscopic surgeries and their interval from primary surgery and gradually decreasing the dose of postoperative hormonal therapy to cure the same and to improve the clinical outcome. Case description: We present a case where a patient underwent curettage after retained products leading to fibrosis of the uterine cavity. Multiple surgeries abroad were unsuccessful to correct the problem. Then patient came to our institute where hysteroscopic adhesiolysis and lateral wall metroplasty along with laparoscopic adhesiolysis and right-sided ovarian cystectomy followed by intrauterine contraceptive device (IUCD) insertion, i.e., multiload without copper was done followed by two more relook hysteroscopic procedures leading to reformation of a normal uterine cavity. The authors discuss the stepwise management of a known case of Asherman\'s syndrome through this successful and challenging case. Conclusion: IUA develop most commonly after vigorous curettage or endometrial tuberculosis. Diagnosis is based on the history and a high index of suspicion and confirmation by SIS and HSG. The hysteroscopic management of IUA is a safe and effective method. It is a surgical pearl for both diagnostic and therapeutic purposes. Sequential estrogen and progesterone therapy and a splint are found to be helpful, but further studies are needed to assess their efficacy. Relook hysteroscopy acts as an adjunctive method to improve the outcome. We emphasize on relook hysteroscopy and its interval from the primary surgery which is usually after next menses when the patient resumes menses as it helps to get a better and long-term clinical outcome. Clinical significance: Hysteroscopy acts as both a diagnostic and therapeutic tool for the management of fibrotic uterine cavity. Relook hysteroscopic surgery is useful to manage a moderate-to-severe degree of fibrotic uterine cavity along with insertion of IUCD without copper to prevent further adhesions. Gradually decreasing the dose of hormonal therapy (estrogen plus progesterone) helps to regenerate the endometrium and to resume normal menses.


PDF Share
  1. Schenker JG. Etiology of and therapeutic approach to synechia uteri. Eur J Obstet Gynecol Reprod Biol 1996;65(1):109–113. DOI: 10.1016/0028-2243(95)02315-j.
  2. Tam WH, Lau WC, Cheung LP, et al. Intrauterine adhesions after conservative and surgical management of spontaneous abortion. J Am Assoc Gynecol Laparosc 2002;9(2):182–185. DOI: 10.1016/s1074-3804(05)60129-6.
  3. Taskin O, Sadik S, Onoglu A, et al. Role of endometrial suppression on the frequency of intrauterine adhesions after resectoscopic surgery. J Am Assoc Gynecol Laparosc 2000;7(3):351–354. DOI: 10.1016/s1074-3804(05)60478-1.
  4. Buttram VC Jr, Turati G. Uterine synechiae: variations in severity and some conditions which may be conductive to severe adhesions. Int J Fertil 1977;22(2):98–103. PMID: 20418.
  5. Asherman JG. Amenorrhea traumatica (atretica). J Obstet Gynaecol Br Emp 1948;55(1):23–30. DOI: 10.1111/j.1471-0528.1948.tb07045.x.
  6. March CM. Intrauterine adhesions. Obstet Gynecol Clin North Am 1995;22(3):491–505. PMID: 8524533.
  7. Schenker JG, Margalioth EJ. Intrauterine adhesions: an updated appraisal. Fertil Steril 1982;37(5):593–610. DOI: 10.1016/s0015-0282(16)46268-0.
  8. Massouras HG. Intrauterine adhesions: a syndrome of the past with the use of the Massouras duck's foot No. 2 intrauterine contraceptive device. Am J Obstet Gynecol 1973;116(4):576–578. DOI: 10.1016/0002-9378(73)90918-6.
  9. Amer MI, Abd-EL-Maeboud KH. Amnion graft following hysteroscopic lysis of intrauterine adhesions. J Obstet Gynecol Res 2006;32(6):559–566. DOI: 10.1111/j.1447-0756.2006.00454.x.
  10. Abott J, Thomson A, Vancaille T. Spraygel following surgery for Asherman's syndrome may improve pregnancy outcome. J Obstet Gynecol 2004;24(6):710–711. DOI: 10.1080/01443610400008206.
  11. Robinson JK, Coliman LM, Isaacson KB. Postoperative adhesiolysis therapy for intrauterine adhesions (Asherman's syndrome). Fertil Steril 2008;90(2):409–414. DOI: 10.1016/j.fertnstert.2007.06.034.
  12. Li C, Wei ML, Lin XN, et al. Effects of early intervention of second look office hysteroscopy in the prevention of adhesion reformation in moderate-severe Asherman's syndrome. Zhonghua Yi Xue Za Zhi 2013 Dec 3;93(45):3617–3619. DOI: 10.3760/cma.j.issn.0376-2491.2013.45.014.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.